1 / 29

High-Altitude Medicine

High-Altitude Medicine. Alicia Bond MD. High altitude. Moderate altitude 5,000 – 10,000 feet above sea level Highest U.S. ski resorts High altitude 10,000 – 18,000 feet above sea level High peaks in the lower 48, Europe Extreme altitude Greater that 18,000 feet above sea level

melia
Télécharger la présentation

High-Altitude Medicine

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. High-Altitude Medicine Alicia Bond MD

  2. High altitude • Moderate altitude • 5,000 – 10,000 feet above sea level • Highest U.S. ski resorts • High altitude • 10,000 – 18,000 feet above sea level • High peaks in the lower 48, Europe • Extreme altitude • Greater that 18,000 feet above sea level • Denali, Himalaya, Karakoram, Andes

  3. Epidemiology • Most cases of high-altitude illness take place in people rapidly ascending to altitudes between 8,000 and 12,000 feet • Can affect people who live at low altitude as well as people who live at high altitude and return from travel to lower altitude (re-entry) • Millions at risk each year – roughly 20-40% affected by some type of altitude illness • 30 million Western states visitors • 12,000 Mt. Everest trekkers • 1,200 Denali climbers • 1 million visitors to extreme high ranges worldwide

  4. High-altitude environments • Decreased barometric pressure = logarithmically lower partial pressure of oxygen (PO2) in inspired air • Higher latitudes have lower barometric pressure at equivalent altitudes • Weather systems can significantly lower barometric pressure transiently • Cold, dry conditions may be contribute to high-altitude illness

  5. Factors affecting risk • Rate of ascent • Recent high-altitude exposure • Genetic variability • Sleeping altitude • Maximum altitude reached

  6. Acclimatization • Series of physiologic adaptations to maintain tissue oxygenation • Ability to acclimatize varies genetically • Hours: Hypoxic ventilatory response (HVR), fluid shift to increase hematocrit, increase in cardiac output • Days: Increased erythropoiesis, return of cardiac function to baseline, increase in 2,3-DPG • Weeks: Increased plasma volume and red blood cell mass

  7. Hypoxic ventilatory response • Most important component of acclimatization • Affected by genetics, ethanol, sleep medications, caffeine, cocoa, progesterone • PaO2 = PiO2 (PaCO2/R) • Hyperventilation decreases the partial pressure of CO2 in the alveoli, thereby increasing the partial pressure of oxygen in the alveoli to facilitate oxygenation • Resulting metabolic alkalosis slows HVR, and ventilation slowly increases over several days as kidneys excrete bicarb • Can be facilitated by acetazolamide • People with low HVR at higher risk for illness

  8. Cardiovascular • Initial increase in resting HR, which normalizes with acclimatization • Decrease in maximal heart rate • Decrease in plasma volume -> lower stroke volume, increase in hematocrit • Shift to extracellular space • Diuresis from bicarbonate excretion • Decrease in max HR and SV are cardioprotective – myocardial ischemia is rare

  9. Hematopoietic response • Initial increase in hematocrit due to fluid shift and diuresis • Erythropoietin stimulated early, resulting in new RBCs within 4-5 days • Over weeks to months, red cell and total circulating volume expand to meet demand

  10. Oxygen-hemoglobin curve • Above 10,000 feet (PO2 ~ 60), small changes in PO2 cause large changes in SaO2 • Initial increase in 2,3-diphosphoglycerate (DPG) promotes O2 release to tissues • Opposed by respiratory alkalosis, which shifts curve left, favoring oxygen uptake in the lung and higher SaO2

  11. Sleep and periodic breathing • Disturbed sleep with less deep sleep and significant arousals common • Periodic breathing common • Hyperpnea and respiratory alkalosis cause apnea • CO2 builds during apnea, causing hyperpnea • Not usually associated with significant hypoxemia or high-altitude illness • Decreases with acclimatization • People with low HVR may have overall regular breathing pattern with periods of more significant apnea and hypoxemia, which are associated with high-altitude illness

  12. Acute high-altitude illness • Spectrum of disease with intertwining pathophysiology • Acute mountain sickness (AMS) • High altitude cerebral edema (HACE) • High altitude pulmonary edema (HAPE) • All correct rapidly with descent

  13. Prevention of high-altitude illness • Avoid ascent to greater than 8,000 feet in one day • Spend 2-3 nights at 8,000-9,000 feet before further ascent • Don’t ascend sleeping altitude more than 1500 feet per day • Limit exertion, alcohol, and sedative-hypnotics during first days at altitude • Day trips to higher altitude while maintaining sleeping altitude can speed acclimatization • Acetazolamide 125-250 mg BID

  14. Acute mountain sickness • Most common with rapid ascent from below 3,000 feet to above 8,000 feet • Develops within hours of ascent • Headache plus at least one of: • Gastrointestinal discomfort • Sleep disturbance • Generalized weakness or fatigue • Dizziness or lightheadedness • Headache is usually throbbing, bitemporal, worse at night and with Valsalva

  15. AMS: Pathophysiology • Pathophysiology incompletely understood • Vasodilatory response to hypoxemia, fluid shift, inflammatory mediators, and alterations in cerebrospinal fluid buffering capacity are all implicated • No evidence of cerebral edema in AMS, but some studies suggest transient ICP elevations with exertion and Valsalva • At risk may be people with low HVR and people with smaller CSF capacity (“tight fit”) • Hyperbaria contributes, but role unclear (AMS does not develop with hypoxia alone)

  16. AMS: Management • Usually resolves within 1-3 days if no additional ascent • Mild: Stop ascent, symptomatic treatment, may consider acetazolamide • Moderate to severe: Low-flow oxygen, acetazolamide +/- dexamethasone 4 mg q 6 hours, hyperbarics, or descend • Immediate descent if s/sx HAPE or HACE

  17. Acetazolamide • Carbonic anhydrase inhibitor • Promotes bicarbonate diuresis and metabolic acidosis, speeding acclimatization • Decreases CSF production • Maintains oxygenation during sleep • Side effects: polyuria and paresthesias • 125-250 mg BID for treatment and prevention of AMS

  18. High-altitude cerebral edema • Least common but most severe form of high-altitude illness • Incidence 1-2% of ascents • Usually develops above 12,000 feet • Usually preceded by AMS and associated with HAPE • Most commonly develops days 1-3 after ascent, but can develop later

  19. HACE: Presentation • Ataxia and altered mentation are hallmarks – ataxia usually first symptom • Focal neuro deficits may be present • Seizures uncommon but reported • Usually preceded by AMS symptoms • Any ataxia or change in consciousness in a person at altitude should elicit immediate action!

  20. HACE: Pathophysiology • Vasogenic cerebral edema caused by same group of mechanisms as AMS (vasodilation, leakage of fluid from vessels) – reversible • Increased ICP causes decreased cerebral blood flow, resulting in cell death • At advanced stages, cytotoxic edema and necrosis are present - not reversible

  21. HACE: Management • Immediate descent is key • High-flow oxygen and dexamethasone 8 mg (IV, IM, PO) followed by 4 mg q 6 hours if available • Hyperbarics may result in temporary improvement but may delay descent • Intubation, hyperventilation if severely altered • Can try mannitol or furosemide but caution due to dehydration common at altitude

  22. HACE: Prognosis • If descent initiated early, may be completely reversible over days to weeks without sequelae • Reports of ataxia and other neuro deficits persisting months to years • Mortality rate greater than 60% if progresses to coma

  23. High-altitude pulmonary edema • Most common cause of altitude-related death • Incidence up to 15% of ascents • Usually greater than 10,000 feet, or greater than 8,000 feet with heavy exertion • Develops within 2-4 days of ascent, classically on the second night

  24. HAPE: Presentation • Early signs are severe dyspnea on exertion, fatigue with minimal activity, and dry cough • Dyspnea at rest and clear, watery sputum develop as illness progresses • Dyspnea at rest is red flag for HAPE and should prompt immediate action! • Patchy infiltrates on CXR, worst right middle lobe

  25. HAPE: Pathophysiology • Hypoxic vasoconstriction causes pulmonary hypertension • Uneven vasoconstriction (areas of extreme hypoxia or anatomic difference) causes hyperperfusion of some areas, leading to vascular leak and patchy edema • Both hypoxia and pulmonary hypertension are exacerbated by exertion

  26. HAPE: Management • Symptoms resolve quickly upon descent of 1500-3000 feet • Mild cases may be treated with bedrest and O2 to maintain SaO2 > 90 • Descent for severe symptoms, minimizing exertion • High-flow oxygen • Continuous positive airway pressure if available • Air drops of O2 may be lifesaving if descent not possible • Hyperbarics may help conserve O2 supply

  27. Hyperbarics • Portable, lightweight,manually-pressurizedhyperbaric bags • Raise atmospheric pressure 2 psi (103 mmHg) • Simulates descent of 4,000-5,000 feet at moderate altitudes, more at higher altitudes • Can be lifesaving in HAPE and HACE, relieving symptoms so that patients can descend without evacuation Photo: Rosen’s Emergency Medicine, Courtesy of Thomas Dietz, MD

  28. Take-home • Slow ascent and acetazolamide are effective in preventing illness • Ataxia, altered mentation, and dyspnea at rest are red flags for serious illness • Early recognition of HAPE and HACE with descent prevents morbidity and mortality • Have fun up there!

  29. Key References • Marx, JA, ed. Rosen’s Emergency Medicine, 7th Ed. Philadelphia: Mosby Elsevier, 2010 • Auerbach, PS, ed. Wilderness Medicine, 6th Ed. Philadelphia: Mosby Elsevier, 2012

More Related